Using antibody-drug combinations to target and eliminate triple-negative breast cancer
Antibody-dual drug conjugates for eradicating triple-negative breast cancer with heterogeneity
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-10877120
This study is working on new treatments for triple-negative breast cancer by creating special drugs that target a protein called TROP2, which could help make the treatment more effective and reduce side effects for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10877120 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative antibody-drug conjugates (ADCs) to effectively treat triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer with limited treatment options. The approach aims to target the TROP2 protein, which is overexpressed in many TNBC tumors, to improve treatment efficacy and overcome drug resistance. By addressing the heterogeneity of TNBC cell populations, the research seeks to enhance therapeutic outcomes and reduce the likelihood of relapse. Patients may benefit from new treatment options that are designed to be more effective and have fewer adverse effects compared to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer, particularly those who have not responded well to existing treatments.
Not a fit: Patients with non-triple-negative breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide more effective treatment options for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise with antibody-drug conjugates in treating various cancers, indicating potential success for this novel approach in TNBC.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TSUCHIKAMA, KYOJI — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: TSUCHIKAMA, KYOJI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.